Vanda Pharmaceuticals (VNDA) Change in Receivables (2010 - 2026)

Vanda Pharmaceuticals (VNDA) has 17 years of Change in Receivables data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 192.07% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $12.3 million (up 56.25% YoY), and the FY2025 full-year result was $7.5 million, down 42.65% from the prior year.
• Change in Receivables declined to $2.3 million in Q1 2026, from $4.1 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $9.1 million in Q2 2023 to a low of -$8.9 million in Q1 2023.
• A 5-year average of $1.4 million and a median of $2.3 million in 2026 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 662.42% in 2023, while the deepest fall reached 829.85% in 2023.
• Tracing VNDA's Change in Receivables over 5 years: stood at $4.1 million in 2022, then climbed by 18.79% to $4.8 million in 2023, then slipped by 8.37% to $4.4 million in 2024, then slipped by 8.03% to $4.1 million in 2025, then sank by 42.75% to $2.3 million in 2026.
• Business Quant data shows VNDA's Change in Receivables at $2.3 million in Q1 2026, $4.1 million in Q4 2025, and $5.6 million in Q3 2025.